Loading clinical trials...
Loading clinical trials...
Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids of these patients, may have important prognostic and diagnostic value not only in HPV-related OPSCCs but also in HPV+ occult T. Accordingly, this study aims to aim to better characterize their potential as biomarkers and to detect the possibility of their their use to implement the sensitivity and specificity of radiological methodologies (PET-CT and MRI), already in use in clinical practice, for monitoring disease progression in this specific subgroup. Finally, by using the collected material to generate organoids and Patient Derived Xenograft (PDX), the study also aims to identify possible new molecular drugs, which could solve the problem of resistance to radiochemotherapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
"Regina Elena" National Cancer Institute
Rome, Italy
Start Date
April 4, 2022
Primary Completion Date
April 4, 2024
Completion Date
April 4, 2029
Last Updated
October 10, 2023
142
ESTIMATED participants
Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
DIAGNOSTIC_TEST
Lead Sponsor
Regina Elena Cancer Institute
Collaborators
NCT04151134
NCT05119036
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00939627